The pricing page is the whole offer
Everything commercial sits on one page. Both GLP-1 plans, all three plan lengths for each, the peptide protocols alongside them, and a statement of what each figure covers. Nothing depends on finding a second page, which is not a small virtue in a category where the qualifier is usually one navigation step away from the number.
The structure is also legible. The one-month rate is the standing rate; the two-month and three-month rates are lower per month and are labelled as what they are. A reader can see the trade between commitment and price without doing any arithmetic themselves.
What the figure covers, and what it does not
The site states the plan price includes the initial telehealth consult, the compounded medication for the selected term, 503A pharmacy fulfilment, cold-chain shipping and asynchronous provider messaging. It also states there are no hidden fees and that a patient can cancel at any time. That is a programme charge that already covers the medication, so nothing sits on top of it.
The stack plans are a different matter. Those bundle a GLP-1 with two or three other compounds under a single figure, and a blend price is not the price of any molecule inside it. Those figures are described on the site and are deliberately not recorded here as semaglutide or tirzepatide prices.
The tirzepatide premium is unusually wide
The gap between the two molecules here is larger than the roster norm, and it holds at every plan length. A reader who assumes the dual-agonist costs a little more will find it costs a great deal more, and the three-month tirzepatide rate still sits above the one-month semaglutide rate.
That is not a criticism of the pricing so much as a warning against reading the entry figure as the price of GLP-1 treatment here. Which molecule a provider recommends will move the bill more than which plan length is chosen.
Sourcing is where it thins out
The pharmacy is described as a 503A licensed facility using FDA-registered active ingredients, which is a category rather than a name. No individual prescribing clinician or medical director is named. No list of states served appears anywhere we read.
The site does state plainly that its compounded products are not FDA-approved and that the FDA does not review them for safety, effectiveness or quality. That candour is worth noting, because it is the sentence a seller has the most commercial reason to bury.
PeptideMD's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $249/moper month on the one-month plan; the same page prices two months at $229 per month and three months at $199 per month, and states the figure covers the consult, the medication and cold-chain shipping | September 2026source |
| Tirzepatide (compounded) | $399/moper month on the one-month plan; the same page prices two months at $369 per month and three months at $329 per month, and states the figure covers the consult, the medication and cold-chain shipping | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 283 providers reviewed here are paid partners today; the other 279 are not. See how this works.
See PeptideMD's current price →Good fit if
- Readers who want one all-inclusive monthly figure with nothing to add on top.
- Patients weighing a longer commitment against a lower rate who want both numbers printed together.
- Anyone who wants the consult, the medication and the shipping stated as covered rather than discovered separately.
- Readers who want the GLP-1 plans and the peptide protocols priced on the same page.
Look elsewhere if
- Patients who need the compounding pharmacy named before taking a compounded medication.
- Readers who must confirm their state is served before starting an intake.
- Anyone choosing tirzepatide on a budget; the premium over semaglutide is wide here and holds at every plan length.
- Readers who want a brand-name, FDA-approved route, which this service does not offer.
How this review was verified
- Read the pricing page and the GLP-1 treatments page at their source URLs and logged each figure with the date it was read.
- Recorded the one-month rate as the standing rate and put the two-month and three-month per-month figures into the qualifier so the commitment travels with the number.
- Did not record the combined GLP-1 and peptide stack figures as a semaglutide or tirzepatide price, because a blend price is not the price of a molecule inside the blend.
- Took the membership position from the pricing page statement that the plan covers care, medication and shipping with no hidden fees.
- Pulled all 3,677 rows of the FDA warning-letter table and filtered them locally with a known-positive and a nonsense-string control in the same run; no letter found.